Serum Erythropoietin and Clinical Outcomes
hospitalizations and mortality. 11, 12 Outside of the HF population, limited data also suggest an increased risk of mortality with elevated serum erythropoietin levels in persons with CKD and in the very old. 13, 14 To our knowledge, there have been no large studies, however, in healthy community-dwelling adults that have evaluated the association of endogenous erythropoietin levels with the spectrum of clinical outcomes seen in trials. In this study, we evaluate the association of serum erythropoietin with incident HF, coronary heart disease (CHD), stroke, mortality, and kidney function decline in a large population of community-dwelling older adults.
Methods Participants
The Health Aging and Body Composition (Health ABC) is a longitudinal study of the impact of changes in weight and body composition on age-related physiologic and functional changes. Communitydwelling adults (N=3075) aged 70 to 79 years were recruited from Medicare eligibility lists from March 1997 to July 1998 at 2 field centers in Pittsburgh, Pennsylvania, and Memphis, Tennessee. White participants were recruited from a random sample of the lists; black participants were recruited from all age-eligible individuals residing in the respective communities. Subjects were eligible if they reported no difficulty walking one fourth of a mile, climbing up 10 steps, or performing basic activities of daily living; were free of lifethreatening illness; planned to remain in the geographic area for ≥3 years; and were not enrolled in lifestyle intervention trials. Exclusion criteria included difficulties with activities of daily living, cognitive impairment, inability to communicate with the interviewer, intention of moving within the next 3 years, and active treatment for cancer in the preceding 3 years. All participants gave informed consent, and the study was approved by the institutional review boards at the University of Tennessee Health Science Center and the University of Pittsburgh. Of the 3075 participants at baseline, 2921 participants were alive and returned for a follow up visit at year 3. Serum erythropoietin was measured in 2499 persons of these participants, and we excluded 11 who were missing cystatin C or albumin to creatinine ratio (ACR) measures, for a final study sample of 2488 ( Figure 1 ).
Exposure Variable
The levels of erythropoietin were measured from frozen-stored serum collected at the year 3 visit. Samples were obtained in the morning after an overnight fast, and after processing, the specimens were frozen at −70°C and shipped to the Core Laboratory at the University of Vermont. Erythropoietin was measured using a monoclonal antibody and polyclonal antibody conjugate in a sandwich ELISA format (Quantikine IVD Human Epo; R&D Systems, Minneapolis, MN) as per the manufacturer's instructions. The sensitivity of the ELISA (minimum detectable level) is <0.6 mIU/mL. The intra-assay coefficient of variation was 7.8% at a mean concentration of 6.45 mIU/mL and 2.4% at a mean concentration of 84.12 mIU/mL.
Outcomes
Surveillance for outcomes was conducted via in-person and alternating phone interviews every 6 months regarding any hospitalizations; when a hospitalization was reported, all records pertaining that were available were collected. Medical records for all overnight hospitalizations were reviewed at each site by local adjudicators. The Health ABC Study Diagnosis and Disease Ascertainment Committee reviewed all hospital records, death certificates, informant interviews, and autopsy data to adjudicate immediate and underlying causes of death. Complete details regarding ascertainment and adjudication of CVD outcomes are provided online (http://keeptrack.ucsf. edu/). Adjudication criteria for HF required, in addition to a physician diagnosis of HF, (1) medical record documentation of symptoms (eg, shortness of breath, fatigue, orthopnea, paroxysmal nocturnal dyspnea) and physical signs (eg, edema, pulmonary rales, gallop rhythm); (2) evidence of pulmonary edema on chest radiography or evidence supporting HF on echocardiography; and (3) medical therapy for HF, including at least a diuretic and either a vasodilator or digitalis. These criteria are similar to those used in the Cardiovascular Health Study. Incident CHD was defined as hospitalization for MI, angina pectoris, or elective coronary revascularization, either surgical or percutaneous. Incident stroke included both fatal and nonfatal stroke events. We divided the cardiac outcomes into HF and CHD because of previous literature showing associations of erythropoietin levels with recurrent HF. 11 While evaluating associations with HF, CHD, and stroke, we excluded persons with these conditions at baseline. Date and causes of death were taken from the death certificate. Progressive decline in kidney function was defined as ≥30% decline in estimated glomerular filtration rate (eGFR) from year 3 visit to year 10. A 30% decline in eGFR has recently been associated with adverse outcomes and therefore recommended as an alternative endpoint for CKD progression. 15 Cystatin C was measured using a BNII nephelometer (Dade Behring Inc, Deerfield, IL) that used a particleenhanced immunonepholometric assay (N Latex Cystatin C). 16 The eGFR was estimated using an equation that included serum cystatin C concentration, age, sex, and race derived in the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) study, 17 and the use of this equation has been validated for change in eGFR over time.
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Covariates
Covariates included sociodemographic factors, such as age, sex, race (self-defined), clinical site; prevalent CVD (history of coronary artery disease and stroke); CVD risk factors, including smoking status defined by current versus former (>100 lifetime cigarettes) or never, diabetes mellitus (defined by use of hypoglycemic agents, self-report, fasting plasma glucose >126 mg/dL, or an oral glucose tolerance test >200 mg/dl); use of individual anti-hypertensives, including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, diuretics, systolic blood pressure; left ventricular hypertrophy (LVH); and heart rate. The Minnesota code criteria were applied to diagnose LVH from the baseline electrocardiogram: R>26 mm in either V5 or V6; or R>20 mm in any of leads I, II, III, aVF; R>12 mm in lead aVL; or R in V5 or V6 plus S in V1 >35 mm. 19 Laboratory values included serum albumin, total cholesterol, C-reactive protein (CRP), interlukin-6 (IL-6), tumor necrosis factors-alpha (TNF-α), eGFR, urine ACR, and serum hemoglobin levels. Serum chemistries were measured by a colorimetric technique on a Johnson & Johnson Vitros 950 analyzer. Measures of IL-6, TNF-α, and CRP were performed using ELISA kits from R&D Systems (Minneapolis, MN). Detectable limits were 0.10 pg/mL for IL-6, 0.18 pg/mL for TNF-α, and 0.007 mg/L for CRP. Interassay coefficients of variation were determined by duplicate analyses of 150 specimens: 10.3%, 8.0%, and 15.8% for IL-6, CRP, and TNF-α, respectively.
20
Statistical Analysis
The starting time for this analysis was year 3 when serum erythropoietin was measured. Although most covariates were available from year 3, a few were only collected at baseline and were therefore carried forward for these analyses. These included serum albumin, CRP, IL-6, TNF-α, urine ACR, LVH, and heart rate. Participants with prevalent HF, CHD, and stroke at year 3 were excluded in the analysis of the respective outcomes. We described the individual distribution of serum erythropoietin using summary statistics and frequency histograms. We then compared baseline participant characteristics (demographics, CVD risk factors, and kidney function measures) across quartiles of serum erythropoietin. Because erythropoietin values were not normally distributed, erythropoietin was log-transformed to the base 2, and analyses were reported per doubling of serum erythropoietin. We evaluated the association of serum erythropoietin with each outcome for the presence of nonlinearity using restricted cubic splines. We performed a time to event analysis to estimate association of serum erythropoietin with HF, CHD events, stroke, and mortality using 3 separate Cox proportional hazards regression models after adjustment for potential confounders. To evaluate the association of erythropoietin with progressive kidney disease, multivariate logistic regression was performed because the outcome can only be reached at one discrete time point when kidney function was measured. Participants with prevalent HF were excluded in analyses evaluating incident HF, and likewise, those with history of CHD and stroke were excluded in the CHD analysis and stroke analyses, respectively. Finally, we constructed Kaplan-Meier curves to assess the probabilities of survival free from HF, CHD, stroke, and death stratified by quartiles of serum erythropoietin.
We used a series of models with sequential adjustment for potential confounding variables. Initial models were adjusted for demographic variables, including age, sex, race, and site. We adjusted for prevalent CVD in all outcomes except CHD and stroke. The second model adjusted for CVD risk factors, including diabetes mellitus, use of antihypertensive medications systolic blood pressure, smoking status, serum albumin, and CRP. Models for HF also included adjustment for heart rate, LVH, IL-6, TNF-α based on previous literature from the Health ABC showing their ability to improve prediction of incident HF. 21, 22 Finally, given the association of serum erythropoietin levels with kidney function and anemia, we further adjusted for eGFR, urine ACR, and serum hemoglobin in our final model.
We then assessed for an interaction between erythropoietin levels and CKD status (eGFR <60 mL/min per 1.73 m2 or ACR >30 mg/g) for each of the clinical outcomes. 2 We also assessed the interaction between erythropoietin levels with presence of anemia (defined as serum hemoglobin <13 g/L in men and <12 g/L in women) and race for HF outcomes given that both anemia and race have been differentially associated with incident HF and mortality in blacks and whites. [23] [24] [25] [26] In sensitivity analysis, we evaluated the competing risk of mortality using the Lunn & McNeill method for HF, incident CVD, and stroke and also evaluated whether our HF results were consistent when patients without prevalent CHD or without incident MI before the HF event were excluded. All analyses were performed using S-Plus (release 8.0; Insightful Inc, Seattle, WA) and SPSS statistical software (release 15.0; SPSS Inc, Chicago, IL). A 2-sided P value <0.05 was considered statistically significant for all analyses, including interaction terms.
Results
The mean age of participants was 75.4±(2.8) years, 51% were female, and 39% were black. The mean eGFR was 79±20 mL/ min per 1.73 m2. The median erythropoietin level (quartile1, quartile 3) was 12.3 (9.0, 17.2) mIU/mL. The distribution of participant characteristics across quartiles of erythropoietin levels is shown in Table 1 . The percentage of blacks increased from 32% in the first quartile to 46% in the highest quartile (P<0.001). Prevalent CAD, HF, and risk factors for CVD, including diabetes mellitus and hypertension and inflammatory markers TNF-α (P=0.006) and IL-6 (P<0.001) were highest in the fourth quartile of erythropoietin. Mean eGFR (P=0.002), serum albumin (P=0.044), and serum hemoglobin (P<<0.001) values were lower with higher erythropoietin quartile.
The mean follow-up time was 10.7 (SD=2.9) years. There were 503 incident HF events (incidence rate 2.5% per year), 330 incident CHD events (2.1%/year), 161 incident strokes (0.8%/ year), 1112 deaths (4.2%/year), and 698 events of kidney function decline (1.2%/year). Unadjusted incidence rates of the all clinical outcomes were highest in the fourth quartile of serum erythropoietin levels. Higher serum erythropoietin levels were associated with increased risk of HF (Figure 2) . In continuous models, each 2-fold higher serum erythropoietin was associated with 30% higher risk of HF after adjusting for prevalent CVD and CVD risk factors. This association remained significant after additional adjustment for kidney function and hemoglobin levels ( Table 2) . After similar adjustments, the highest quartile (≥17.18 mIU/mL) of serum erythropoietin had 1.25 (95% confidence interval 1.01-1.89) times increased risk of HF compared with the lowest quartile (<9.04 mIU/mL). There was no association between higher erythropoietin levels with CHD, stroke, all-cause mortality, or progressive decline in kidney function. Figure 3 shows the Kaplan-Meir curves for each of the outcomes by quartiles of serum erythropoietin.
The presence of CKD did not significantly modify the effect of erythropoietin levels on HF (P=0.82), CHD (P=0.15), stroke (P=0.81), mortality (P=0.49), or eGFR decline (P=0.15). There was also no significant interaction between serum erythropoietin with either race (P= 0.50) or presence of anemia (P=0.81) with respect to the outcome of HF.
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In a sensitivity analysis evaluating the competing risk of mortality with the other clinical outcomes, our results were unchanged (Table in the Data Supplement). In another sensitivity analysis, we found that of the 503 participants who developed incident HF, 152 had prevalent CHD and 19 developed incident MI before development of HF. In the remaining 332 participants, we evaluated the association between endogenous erythropoietin level and risk of HF. Each SD higher erythropoietin level was associated with a 27% increased risk of HF (hazard ratio 1.27, 95% confidence interval 1.07, 1.50), and compared with the lowest quartile, persons in the highest quartile of serum erythropoietin had 41% increased risk of HF (hazard ratio 1.41, 95% confidence interval 1.01, 2.02).
Discussion
In this large cohort of community-dwelling older adults, we found that higher levels of endogenous erythropoietin were associated with risk of incident HF after adjusting for demographic variables, prevalent CVD, CVD risk factors, inflammatory markers, kidney function, and hemoglobin level. A number of studies have demonstrated that levels of endogenous erythropoietin are higher in persons with prevalent HF and that they correlate with severity of disease. 11, [27] [28] [29] Elevated levels of erythropoietin are also associated with mortality 11,12,27,28 and may be able to discriminate those who are likely to be hospitalized for recurrent HF or die during 0.639 221 (9) ACE-I indicates angiotensin converting enzyme inhibitors; ACR, albumin to creatinine ratio; ARBs, angiotensin receptor blockers; BP med, blood pressure medication; CAD, coronary artery disease; CCB-calcium channel blockers; CKD, chronic kidney disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HF, heart failure; IL-6, interleukin 6; LVH, left ventricular hypertrophy; SBP, systolic blood pressure; TNF-α, tumor necrosis factor alpha.
All values expressed as % or mean (SD) except *Defined as serum hemoglobin <13 gm/L in men and <12 gm/L in women; and †Median (quartile 1, quartile 3). Serum Erythropoietin and Clinical Outcomes follow-up. 11 Our results add to this literature by demonstrating an association of endogenous erythropoietin levels with incident HF. We did not find any significant associations between serum erythropoietin levels with CHD, stroke, mortality, or progressive kidney function decline.
Large clinical trials of ESAs have noted a significantly greater risk of adverse outcomes in persons randomized to ESA treatment relative to placebo. The Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) noted an elevated risk of stroke but not HF in those receiving ESA therapy as compared with placebo, 30 and the Reduction of Events by Darbepoetin Alfa in Heart Failure (RED-HF) trial noted a trend toward increased risk of stroke and thrombotic events with ESA therapy compared with placebo. 9 Among patients with prevalent HF and CHD undergoing dialysis, the Normal Hematocrit Study found an increased risk of death and nonfatal MI in those randomized to the normal hematocrit arm, 31 and in persons with CKD, the Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) trial showed a 41% increased risk of HF-related hospitalizations (P=0.07) in addition to higher risk for MI, stroke, and mortality 6 in those randomized to higher hemoglobin targets with ESA therapy. Studies have attempted to elucidate whether the relationship between ESA and adverse CVD outcomes are directly through ESA or mediated by the hemoglobin levels achieved. Post hoc analyses from both the CHOIR and TREAT studies have suggested that participants who were unable to achieve target hemoglobin values despite incremental doses of ESA (suggesting a hyporesponsive bone marrow) were at particularly higher risk of adverse outcomes compared with those who achieved their target hemoglobin values. 32, 33 However, in a more recent analysis of the CHOIR results, it was noted that irrespective of the hemoglobin response, participants who were maintained on a higher dose of ESA had an elevated risk of adverse clinical outcomes. 34 These findings may suggest that the dose of ESA used rather than the There are several potential mechanisms through which erythropoietin may be associated with cardiovascular outcomes. First, the elevation of hemoglobin with ESA therapy pressure; CHD, coronary heart disease; CI, confidence interval; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HF, heart failure; HR hazard ratio; IL-6, interleukin 6; TNF-α, tumor necrosis factor alpha; and UACR, urine albumin to creatinine ratio.
*Adjusted for age, sex, race and site, diabetes mellitus, BP medication systolic blood pressure, smoking status, serum albumin, CRP. All models included adjustment for prevalent cardiovascular disease except for the outcome of incident CHD and incident stroke. Models for the HF also included adjustment for heart rate, left ventricular hypertrophy, IL-6, TNF-α, and individually for angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, and diuretics.
†Further adjusted eGFR, UACR, and serum hemoglobin. Serum Erythropoietin and Clinical Outcomes may result in increased blood volume and viscosity, leading to strokes, hypertension, and left ventricular remodeling. More recent analyses indicate that elevated hemoglobin levels do not independently confer increased risk independent of ESA dosing, and we noted higher risk for HF even after adjustment for levels of hemoglobin. 34 Second, erythropoietin has a number of nonhematopoietic roles, including anti-apoptotic and antioxidant properties, and has been shown to promote angiogenesis in the heart. 35, 36 It has been hypothesized that because of its pleotrophic properties on angiogenesis, platelet aggregation, and tumorigenesis, chronic exposure to elevated levels of erythropoietin may have a causal role in the development of adverse cardiovascular events. 11, 13, 34, 37 Through numerous receptors in the heart, erythropoietin plays a cardioprotective role during ischemia-reperfusion injury by preventing apoptosis and promoting ventricular remodeling. 38, 39 However, it has been hypothesized that chronic stimulation of these receptors because of elevated or supra therapeutic levels of circulating erythropoietin may lead to disordered remodeling and adverse outcomes. 40 Third, elevations in endogenous erythropoietin and the need for high-dose ESA in trials may reflect a hypo-responsive bone marrow, which in turn may reflect overall poorer health status. 28, 32, 41 Hypo-responsiveness to erythropoietin may also reflect underlying levels of chronic inflammation (clinical or subclinical). 42, 43 Our findings of increased HF risk persisted, however, despite adjusting for inflammatory markers, such as CRP, TNF-α, and IL-6, as well as comorbid conditions.
We did not note an increased risk of CHD events, stroke, mortality, or decline in kidney function in our study, in contrast to the trends seen in trials of ESA therapy. It is possible that this difference is related to the absolute erythropoietin levels achieved with exogenous ESA where intravenous administration of as little as 3000 U can cause a peak serum erythropoietin level of nearly 1000 mIU/L, which is over 50 times the value Figure 3 . Kaplan-Meir curves of clinical outcomes by serum erythropoietin levels. Unadjusted Kaplan-Meir curves for incident heart failure, CHD, stroke, and death by quartile of serum erythropoietin at year 3. CHD indicatescoronary heart disease. Serum Erythropoietin and Clinical Outcomes of the highest quartile in our study. 44 One could also hypothesize that the chronic but relatively low-grade elevation of serum erythropoietin in our study is sufficient to exert adverse effects on cardiac myocytes and increase risk of HF, but not influence other outcomes. We found that excluding persons with prevalent CHD and MI before the development of HF did not alter our primary results, which suggest that the association between erythropoietin and HF may be mediated through non-atherosclerotic mechanisms. Finally, it is possible that the rapid rise and fall of serum erythropoietin following exogenous ESA administration, which is distinctly different from the low-grade sustained elevation seen in our study, differentially affects clinical outcomes.
Our study has a number of limitations. First, the observational nature of the study precludes our ability to ascribe cause-effect relationships. Although we adjusted for a number of potential confounders and inflammatory markers, residual or unmeasured confounding cannot be ruled out. Second, our study was not designed to evaluate the predictive value of serum erythropoietin for clinical events and whether measurement leads to a change in outcomes; therefore, we would not currently recommend measurement of serum erythropoietin in this population. Third, our population only included elderly blacks and whites and only a relatively small proportion had advanced CKD; therefore, it remains unknown whether the results are generalizable to younger populations, those of different ethnicities and with more advanced CKD. Fourth, because some patients may have developed HF without reporting the event, our rates of HF may have been underestimated. Finally, because of the study design and timing of data collection, a number of covariates (CRP, IL-6, TNF-α, urine ACR, LVH, and heart rate) which were included in our regression models were collected only at baseline and needed to be carried forward to year 3. This is important given that some of these independently predict incident HF. Our study also has a number of strengths. It is the largest study of endogenous erythropoietin levels in a community-dwelling general population. The Health ABC cohort has detailed ascertainment of risk factors, covariates, and outcomes and the ability to adjust for measures of kidney function and inflammation. We also used a laboratory that has extensive experience with these measures.
Conclusions
Well-functioning community-living older persons with elevated levels of serum erythropoietin are at increased risk of incident HF. This association is independent of cardiovascular risk factors, inflammatory markers, kidney function, and serum hemoglobin. This finding is consistent with those from randomized trials, suggesting that high erythropoietin may lead to adverse clinical outcomes. Further studies are needed to evaluate the mechanisms explaining the results.
CLINICAL PERSPECTIVE
Therapy with high doses of erythropoietin-stimulating agents is associated with higher risk of adverse events in dialysis patients and those with heart failure. Although endogenous erythropoietin levels are elevated in the setting of prevalent heart failure and increase the risk of re-hospitalization, the association of erythropoietin with clinical outcomes in the general population is relatively unknown. We found that elevated levels of endogenous erythropoietin were associated with increased risk of incident heart failure over 10 years of follow-up in community-dwelling adults aged 70-79 years enrolled in the Health ABC study. This novel association was independent of baseline hemoglobin, kidney function, and other risk factors for heart failure. It is unknown, however, whether elevated levels of erythropoietin reflect a state of inflammation, thus serving as a marker of increased HF risk or whether erythropoietin is causally associated with incident heart failure. If causal, it may be that the untoward effects of elevated erythropoietin are mediated by nonatherosclerotic mechanisms given the lack of increased risk of coronary events or stroke associated with higher levels. Further studies are needed to evaluate whether serum erythropoietin levels can be used to predict incident heart failure before routine measurement in clinical practice can be recommended.
